OPKO Health, Inc. (NASDAQ:OPK) CEO Buys $162,000.00 in Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 100,000 shares of the stock in a transaction that occurred on Thursday, November 14th. The shares were purchased at an average price of $1.62 per share, with a total value of $162,000.00. Following the purchase, the chief executive officer now owns 211,612,405 shares of the company’s stock, valued at approximately $342,812,096.10. This represents a 0.05 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Friday, November 8th, Phillip Md Et Al Frost bought 280,183 shares of OPKO Health stock. The shares were purchased at an average price of $1.50 per share, with a total value of $420,274.50.

OPKO Health Price Performance

OPK traded up $0.02 on Thursday, hitting $1.62. 5,502,989 shares of the company were exchanged, compared to its average volume of 6,965,010. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. The business’s fifty day moving average is $1.51 and its 200 day moving average is $1.43. OPKO Health, Inc. has a fifty-two week low of $0.85 and a fifty-two week high of $1.75. The firm has a market capitalization of $1.11 billion, a P/E ratio of -8.42 and a beta of 1.65.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Piper Sandler restated an “overweight” rating and issued a $3.00 price objective on shares of OPKO Health in a research note on Tuesday, September 17th. StockNews.com upgraded shares of OPKO Health to a “sell” rating in a research note on Saturday, July 27th. Barrington Research restated an “outperform” rating and issued a $2.25 price objective on shares of OPKO Health in a research note on Friday, November 8th. Finally, HC Wainwright restated a “buy” rating and issued a $3.00 price objective on shares of OPKO Health in a research note on Thursday, September 26th.

Institutional Trading of OPKO Health

Large investors have recently modified their holdings of the business. CIBC Asset Management Inc boosted its position in OPKO Health by 79.1% during the second quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 8,978 shares during the last quarter. Hollencrest Capital Management increased its stake in OPKO Health by 14.0% during the 2nd quarter. Hollencrest Capital Management now owns 90,000 shares of the biotechnology company’s stock worth $112,000 after buying an additional 11,020 shares during the period. FMR LLC increased its stake in OPKO Health by 103.6% during the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after buying an additional 11,089 shares during the period. Price T Rowe Associates Inc. MD increased its stake in OPKO Health by 4.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 445,981 shares of the biotechnology company’s stock worth $536,000 after buying an additional 17,671 shares during the period. Finally, Virtu Financial LLC acquired a new position in OPKO Health during the 1st quarter worth $26,000. 64.63% of the stock is currently owned by institutional investors and hedge funds.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.